Bladder cancer has transitioned from a chemotherapy-dominated disease to one driven by immunotherapy and rational combinations. While platinum-based chemotherapy once defined outcomes, survival remained limited, particularly in metastatic disease.
Over the past decade, a sequence of pivotal trials has not only introduced immune checkpoint inhibitors but has also redefined treatment timing, combinations, and patient selection—ultimately reshaping survival expectations.
Bladder Cancer: Symptoms ,Causes, Stages, Diagnosis and Treatment
Checkpoint Inhibition as the First Turning Point
The phase III KEYNOTE-045 trial established pembrolizumab as standard therapy after platinum failure, demonstrating both improved survival and durable responses.
- Overall Survival (OS): 10.3 vs 7.4 months (HR 0.73)
- Progression-Free Survival (PFS): 2.1 vs 3.3 months (no PFS advantage, but OS benefit driven by durability)
This paradox—limited PFS benefit but improved OS—highlighted a defining feature of immunotherapy: long-term responders drive survival curves.
Similarly, CheckMate 275 confirmed nivolumab activity in this setting, with meaningful response rates and durable benefit, particularly in PD-L1–expressing tumors.
Maintenance Immunotherapy: A Paradigm Shift
The phase III JAVELIN Bladder 100 trial introduced switch-maintenance immunotherapy with avelumab after first-line chemotherapy, redefining treatment sequencing.
- Overall Survival (OS): 21.4 vs 14.3 months (HR 0.69)
- Progression-Free Survival (PFS): 3.7 vs 2.0 months
This study demonstrated that early introduction of immunotherapy—before progression—significantly prolongs survival, establishing maintenance therapy as a standard of care.
ADC + Immunotherapy: The Most Transformative Advance
The phase III EV-302 / KEYNOTE-A39 trial represents the most significant recent breakthrough, evaluating enfortumab vedotin + pembrolizumab in the first-line setting.
- Overall Survival (OS): ~31.5 vs 16.1 months (HR ~0.47)
- Progression-Free Survival (PFS): ~12.5 vs 6.3 months (HR ~0.45)
These results demonstrate a doubling of survival compared with chemotherapy, with unprecedented response rates and a substantial proportion of complete responses.
This combination has rapidly become a preferred first-line standard, marking a shift away from chemotherapy-based regimens.
10 Ongoing Clinical Trials on Immunotherapy in Bladder Cancer
Immunotherapy in the Perioperative Setting
The phase III CheckMate 274 trial extended immunotherapy into the adjuvant setting following radical cystectomy in high-risk disease.
- Disease-Free Survival (DFS): 20.8 vs 10.8 months (HR 0.70)
- Overall Survival (OS): immature at initial reporting
This trial established adjuvant nivolumab as a standard option, particularly in high-risk patients, and marked the expansion of immunotherapy into curative-intent treatment strategies.
Ongoing perioperative trials (e.g., KEYNOTE-905 / EV-303) are evaluating combination strategies earlier in the disease course, with the goal of improving cure rates.
Non–Muscle-Invasive Disease: Beyond BCG
The phase II KEYNOTE-057 trial introduced pembrolizumab for BCG-unresponsive NMIBC with carcinoma in situ.
- Complete Response Rate (CR): ~41%
- Median Duration of Response: ~16 months
Although not traditionally assessed with OS/PFS endpoints, these results are clinically meaningful, offering a bladder-preserving option in a setting previously dominated by cystectomy.
Biomarker-Guided Immunotherapy
Efforts to refine immunotherapy use are increasingly focused on molecular selection. The ongoing IMvigor011 trial is evaluating ctDNA-guided adjuvant atezolizumab, aiming to identify patients with minimal residual disease who derive the greatest benefit.
This represents a shift toward precision immunotherapy, where treatment decisions are guided by tumor biology rather than clinical staging alone.
Insights
The evolution of immunotherapy in bladder cancer reflects a layered transformation. Checkpoint inhibitors first introduced durable responses, maintenance strategies optimized treatment timing, and ADC–immunotherapy combinations have now delivered the most profound survival gains observed to date.
Importantly, the field is moving beyond metastatic disease, integrating immunotherapy into perioperative and early-stage settings, while biomarker-driven approaches promise to further refine patient selection.
Key Takeaway Message
- Immunotherapy has replaced chemotherapy as the foundation of bladder cancer treatment
- Avelumab maintenance improves overall survival when introduced early
- Enfortumab vedotin + pembrolizumab significantly prolongs OS and PFS and is now a first-line standard
- Immunotherapy is expanding into earlier-stage disease, including perioperative settings
- The field is moving toward biomarker-guided treatment (e.g., ctDNA)
You Can Watch More on OncoDaily Youtube TV